<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

Tofacitinib citrate - CP 690550-10

產(chǎn)品貨號(hào)

Axon 2072 CAS [540737-29-9] MF C16H20N6O.C6H8O7MW 504.49 Purity: 99% Soluble in DMSO Description Potent Janus Kinase 3 (JAK3) inhibitor; an immunosuppressive agent exhibiting potent effects in preclinical transplantation and arthritis models; clinically safe and effective in preventing transplant rejection and improving symptoms of rheumatoid arthritis and psoriasis; the citrate salt form of CP 690550 - Tofacitinib (Axon 1338) References Certificates Categories Extra info AC Papageorgiou et al.?Is JAK3 a new drug target for immunomodulation-based therapies??Trends Pharmacol. Sci. 2004, 25(11), 558-562. ? E Kudlacz et al.?The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models.?Am. J. Transplant.?2004, 4, 51-57. ? E Kudlacz et al.?The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia.?Eur. J. Pharmacol.?2008, 582, 154-161. ? PS Changelian et al.?Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor. Sci. 2003, 302(5646), 875-878. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Epigenetics Immunology Pain & Inflammation Immunomodulator JAK-STAT EC 2.7.10.2 JAK Pfizer Licensed Products Potent Janus Kinase 3 (JAK3) inhibitor Chemical name 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [477600-75-2] Order Size Unit Price Stock 10 mg €115.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

Tofacitinib citrate - CP 690550-10

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 2072

CAS [540737-29-9]

MF C16H20N6O.C6H8O7
MW 504.49

Purity: 99%
Soluble in DMSO

Tofacitinib citrate

Description

Potent Janus Kinase 3 (JAK3) inhibitor; an immunosuppressive agent exhibiting potent effects in preclinical transplantation and arthritis models; clinically safe and effective in preventing transplant rejection and improving symptoms of rheumatoid arthritis and psoriasis; the citrate salt form of CP 690550 - Tofacitinib (Axon 1338)

AC Papageorgiou et al.?Is JAK3 a new drug target for immunomodulation-based therapies??Trends Pharmacol. Sci. 2004, 25(11), 558-562.

E Kudlacz et al.?The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models.?Am. J. Transplant.?2004, 4, 51-57.

E Kudlacz et al.?The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia.?Eur. J. Pharmacol.?2008, 582, 154-161.

PS Changelian et al.?Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor. Sci. 2003, 302(5646), 875-878.

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology Epigenetics Immunology Pain & Inflammation Immunomodulator JAK-STAT EC 2.7.10.2 JAK Pfizer Licensed Products

Potent Janus Kinase 3 (JAK3) inhibitor

Chemical name

3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[477600-75-2]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>